Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: A randomized pilot study (E-184V study)

AIDS

Volumn 20, Issue 6, 2006, Pages 795-803

  Castagna, Antonella ^a   Danise, Anna ^a   Menzo, Stefano ^b   Galli, Laura ^a   Gianotti, Nicola ^a   Carini, Elisabetta ^a   Boeri, Enzo ^a   Galli, Andrea ^a   Cernuschi, Massimo ^a   Hasson, Hamid ^a   Clementi, Massimo ^a   Lazzarin, Adriano ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

HIV; Lamivudine monotherapy; M184V mutation; Replication capacity; Salvage therapy; Treatment interruption

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; BACTERIAL PNEUMONIA; CAROTID ARTERY OBSTRUCTION; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; DEATH; DISEASE SEVERITY; DRUG TREATMENT FAILURE; FEMALE; HEART INFARCTION; HEPATITIS A; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MALE; MONOTHERAPY; PELVIC INFLAMMATORY DISEASE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REBOUND; SIDE EFFECT; THRUSH; TREATMENT OUTCOME; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; PILOT PROJECTS; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT FAILURE; TREATMENT OUTCOME; VIRAL LOAD; VIRUS REPLICATION;

EID: 33646682878     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000218542.08845.b2     Document Type: Article

References (24)

1. Deeks SG, Grant RM, Wrin T, Paxinos EE, Liegler T, Hoh R, et al. Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response. AIDS 2003;17:361-370.
2. Katlama C, Dominguez S, Gourlain K, Duvivier C, Delaugerre C, Legrand M, et al. Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097). AIDS 2004; 18:217-226.
3. Deeks SG, Vrin BS, Liegler T, Hoh R, Hayden M, Barbour JD, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001; 344:472-480.
4. Lawrence J, Mayers DL, Hullsiek KH, Collins G, Abrams DI, Reisler RB, et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 2003; 349:837-846.
5. Ghosn J, Winden M, Ktorza N, Peytavin G, Ait-Mohand H, Schneider L, et al. No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients. AIDS 2005; 19:1643-1647.
6. Ruiz L, Ribera E, Bonjoch A, Romeu J, Martinez-Picado J, Paredes R, et al. Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study. J Infect Dis 2003; 188:977-985.
7. Antinori A, Cingolani A, Perno CF. Structured treatment interruption in HIV-infected patients failing on multidrug therapy: is there a future for this strategy? AIDS 2005; 19:1691-1694.
8. d'Arminio Monforte A, Cozzi-Lepri A, Phillips A, De Luca A, Murri R, Mussini C, et al. Interruption of highly active antiretroviral therapy in HIV clinical practice: results from the Italian Cohort of antiretroviral-naive patients. J Acquir Immune Defic Syndr 2005; 38:407-416.
9. Li X, Margolick JB, Conover CS, Badri S, Riddler SA, Witt MD, Jacobson LP. Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 2005; 38:320-328.
10. Schuurman R, Nijhuis M, van Leeuwen P, Schipper P, de Jong D, Collis P, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus population in persons treated with lamivudine (3TC). J Infect Dis 1995; 171:1411-1419.
11. Wainberg MA, Drosopoulos WC, Salomon H, Hsu M, Borkow J, Parniak M, et al. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 1996; 271:1282-1285.
12. Lu J, Kuritzskes DR. A novel recombinant marker virus assay for comparing the relative fitness of HIV-1 reverse transcriptase variants. J Acquir Immune Defic Syndr 2001; 27:7-13.
13. Wei X, Liang C, Gotte M, Wainberg MA. The M184V mutation in HIV-1 reverse transcriptase reduces the restoration of wildtype replication by attenuated viruses. AIDS 2002; 16:2391-2398.
14. Quan Y, Brenner BG, Oliveira M, Wainberg MA. Lamivudine can exert a modest antiviral effect against human immunodeficiency virus type 1 containing the M184V mutation. Antimicrob Agents Chemother 2003; 47:747-754.
15. Eron JJ Jr, Bartlett JA, Santana JL, Bellos NC, Johnson J, Keller A, Kuritzkes DR. Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation. J Acquir Immune Defic Syndr 2004; 37:1581-1583.
16. Campbell TB, Shulman NS, Johnson SC, Zolopa AR, Young RK, Bushman I, et al. Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. Clin Infect Dis 2005; 41:236-242.
17. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, Pillay D, et al. Update of drug resistance mutations in HIV-1:2005. Top HIV Med 2005; 13:51-57.
18. Menzo S, Rusconi S, Monachetti A, Colombo MC, Violin M, Bagnarelli P, et al. Quantitative evaluation of the recombinant HIV-1 phenotype to protease inhibitors by a single-step strategy. AIDS 2000; 14:1101-1110.
19. Menzo S, Monachetti A, Balotta C, Corvasce S, Rusconi S, Paolucci S, et al. Processivity and drug-dependence of HIV-1 protease: determinants of viral fitness in variants resistant to protease inhibitors. AIDS 2003; 17:663-671.
20. Goicoechea M, Haubrich R. CD4 lymphocyte percentage versus absolute CD4 lymphocyte count in predicting HIV disease progression: an old debate revisited. J Infect Dis 2005; 192:945-947.
21. Burcham J, Marmor R, Dubin M, Tindall B, Cooper DA, Berry G, Penny R. CD4% is the best predictor of development of AIDS in a cohort of HIV-infected homosexual men. AIDS 1991; 5:365-372.
22. 3. J Infect Dis 2005; 192:950-957.
23. Barbour JD, Hecht FM, Wrin T, Segal MR, Ramstead CA, Liegler TJ, et al. Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment naive adults in early HIV-1 infection. J Infect Dis 2004; 190:251-256.
24. Daar ES, Kesler KL, Wrin T, Petropoulo CJ, Bates M, Lail A, et al. HIV-1 pol replication capacity predicts disease progression. AIDS 2005; 19:871-877.